<DOC>
	<DOCNO>NCT01365663</DOCNO>
	<brief_summary>The purpose study study safety tolerability SPC4955 healthy subject .</brief_summary>
	<brief_title>Multiple Ascending Dose Study SPC4955 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<criteria>1 . Healthy male female subject , age 1865 year , inclusive . 2 . BMI 1833 kg/m2 3 . Screening hematology , clinical chemistry , coagulation urinalysis consistent overall good health follow criterion meet : LDLC ≥3.24 mmol/L ( ≥125 mg/dL ) Triglycerides ( fast ) &lt; 2.7mmol/L ( &lt; 239 mg/dL ) ALT within normal limit 1 . Any uncontrolled active major systemic disease include , limited : cardiovascular , pulmonary , gastrointestinal , metabolic , urogenital , neurological , immunological , psychiatric , neoplastic disorder metastatic potential . 2 . History presence malignancy within past year . Subjects successfully treat ( 3 month longer ) recurrence basal cell carcinoma skin carcinoma insitu cervix may enrol 3 . Active acute chronic infection , include , limited : upper airway infection , urinary tract infection , skin infection 4 . Use prescription medication within 14 day prior plan first drug administration throughout study . 5 . Use nonprescription overthecounter medication prohibit within 7 day prior plan first drug administration throughout study . This include vitamin , herbal supplement , remedy . 6 . Positive result follow Screening laboratory test : urine pregnancy test ( woman ) , alcohol breath test , urine drug abuse , hepatitis B surface antigen , hepatitis C antibody , human immunodeficiency virus ( HIV ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>LDL</keyword>
	<keyword>HDL</keyword>
	<keyword>apoB</keyword>
	<keyword>hyperlipidemia</keyword>
	<keyword>LNA-oligonucleotide</keyword>
</DOC>